SCHEMBL4635677

SCHEMBL4635677

CCOC(=O)N1CCC(Nc2cc(OC)ccc2N)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 5/20 0.63
NOS1 P29475 4/20 0.63
NOS3 P29474 2/20 0.63
HPGD P15428 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
KDM4E B2RXH2 2/20 0.50
LMNA P02545 2/20 0.50
TSHR P16473 1/20 0.50
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 4/20 0.49
USP2 O75604 2/20 0.49
MAPT P10636 2/20 0.49
HSD17B10 Q99714 1/20 0.49
MAP4K4 O95819 1/20 0.48
CDK1 P06493 1/20 0.47
CDK4 P11802 1/20 0.47
CCND1 P24385 1/20 0.47
CDK2 P24941 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635529 0.87 NOS2 (0.61) NOS2NOS1NOS3NPSR1KDM4E
SCHEMBL22587904 0.85 ALDH1A1 (0.68) NOS2NOS1NOS3L3MBTL1ALDH1A1
SCHEMBL4669485 0.85 ALDH1A1 (0.57) NOS2NOS1NOS3NPSR1KDM4E
SCHEMBL4635773 0.85 NOS2 (0.62) NOS2NOS1NOS3HPGDNPSR1
SCHEMBL4635816 0.83 NOS2 (0.59) NOS2NOS1NOS3HPGDNPSR1
SCHEMBL605250 0.82 LMNA (0.55) NOS2NOS1NOS3HPGDNPSR1
SCHEMBL4918724 0.82 NOS2 (0.62) NOS2NOS1NOS3HPGDKDM4E
SCHEMBL8257196 0.80 NOS2 (0.61) NOS2NOS1NOS3NPSR1KDM4E
SCHEMBL16408358 0.80 MAPT (0.54) NOS2NOS1NOS3HPGDKDM4E
SCHEMBL14180558 0.80 KDM4E (0.58) NOS2NOS1NOS3HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
EP-1937670-A1 BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR GLAXO GROUP LIMITED (GB) 2008-07-02 EP disclosed
WO-2007036711-A1 BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR GLAXO GROUP LIMITED (GB) 2007-04-05 WO disclosed
WO-2007036711-A1 BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR GLAXO GROUP LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor CHRM1, CHRM2, CHRM4 NOS2 2065/4885NOS1 1083/4885NOS3 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.